This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04883/identifier/bindingdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04883/identifier/pubchem-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB04883/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04883/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04883/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04883
rdf:type
n3:Drug
n3:description
Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
n3:generalReferences
# Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ: Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study. J Clin Hypertens (Greenwich). 2007 Oct;9(10):760-769. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17917503 # Kruschewski M, Anderson T, Loddenkemper C, Buhr HJ: Endothelin-1 receptor antagonist (LU-135252) improves the microcirculation and course of TNBS colitis in rats. Dig Dis Sci. 2006 Aug;51(8):1461-70. Epub 2006 Jul 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16868834 # Gradman AH, Vivas Y: New drugs for hypertension: what do they offer? Curr Hypertens Rep. 2006 Oct;8(5):425-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16965731
n3:group
investigational
n3:indication
For the treatment of congestive heart failure and hypertension.
owl:sameAs
n6:DB04883
dcterms:title
Darusentan
adms:identifier
n9:154336 n10:DB04883 n11:50108202 n12:177236 n13:10258564
n3:mechanismOfAction
The mode of action by which the endothelin receptor antagonists cause a decrease of the BP is not yet totally elucidated; however, peripheral vasodilatation due to blockade of the vasoconstrictor effects of endothelin is the most likely explanation. A reduction of cardiac contractility is considered unlikely. Several studies have been published that investigated the effects of either selective or nonselective endothelin receptor blockade in patients with heart failure. In these studies, application of endothelin antagonists, while decreasing both systemic and pulmonary BP increased cardiac index and did not alter cardiac contractility or heart rate.
n3:IUPAC-Name
n4:271B5CC3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5CC9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5CC8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5CC5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5CC6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5CC7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5CC1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5CBF-363D-11E5-9242-09173F13E4C5 n4:271B5CC2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5CC0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5CCF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5CD0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5CCA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5CCB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5CCD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5CCC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5CCE-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
171714-84-4
n3:Bioavailability
n4:271B5CD5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5CD7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5CD8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5CD4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5CD3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5CD6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5CC4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5CD1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5CD2-363D-11E5-9242-09173F13E4C5